Highlights Of The Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program 2026

DAY 1 :
WEDNESDAY, 14 OCTOBER, 2026
08:00 - 08:50
REGISTRATION AND MORNING REFRESHMENTS
08:50 - 09:00
OPENING ADDRESS
09:00 - 09:25
ACCELERATING NEOANTIGEN PEPTIDE CLINICAL TRIALS
Christian Stumpp
Intavis Peptide Services GmbH

Christian Stumpp

Intavis Peptide Services GmbH

  • Leveraging personalised cancer vaccines to reduce recurrence with high efficacy
  • Minimising off-target effects by tailoring neoantigen peptides for each patient
  • Streamlining supply chains for quality, speed, and cost in trial-scale production
09:25 - 09:30
Q&A SESSION ON NEOANTIGEN VACCINE MANUFACTURING STRATEGIES
09:30 - 09:55
HOW THE RISE OF ORAL PEPTIDES LIKE ICOTYDE TRIGGERS THE REVIVAL OF LPPS TECHNOLOGIES
Gildas Deniau
Johnson & Johnson Innovative Medicine

Gildas Deniau

Johnson & Johnson Innovative Medicine

  • Introducing icotrokinra as the first oral IL-23 receptor inhibitor and reviewing its key structural features
  • Positioning oral peptides as a growing modality bridging small molecules and antibody-based injectables
  • Scaling oral peptides to therapeutic volumes while meeting high API demand and cost-of-goods targets
  • Comparing liquid-phase and fragment-based strategies against traditional SPPS for commercial supply
09:55 - 10:00
Q&A SESSION ON ORAL PEPTIDES AND LPPS MANUFACTURING REVIVAL
10:00 - 10:30
SPEED NETWORKING SESSION
  • Exchange business cards and get connected in short one-to-one meetings
  • Start the conversation to arrange a more formal meeting later on in the conference
  • Share your professional background and discuss your biggest business issues — don't forget your business cards!
10:30 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON PEPTIDE DRUG
11:30 - 11:55
SEEING MORE, TREATING SMARTER: THE EVOLVING ROLE OF PSMA IN PROSTATE CANCER
Alexander Wibisono
Klinikum Bayreuth GmbH

Alexander Wibisono

Klinikum Bayreuth GmbH

  • Benchmarking PSMA-PET/CT against bone scan and mpMRI for prostate cancer staging and restaging
  • Pinpointing interpretation pitfalls and tracer-related artefacts in clinical PSMA-PET/CT practice
  • Rethinking care strategies when Lu-177-PSMA radioligand therapy no longer controls disease
11:55 - 12:00
Q&A SESSION ON PSMA DIAGNOSTICS AND RADIOLIGAND THERAPY IN PROSTATE CANCER
12:00 - 12:30
RESERVED PRESENTATION
12:30 - 13:30
NETWORKING LUNCH AND VISITING THE PEPTIDE DRUG EXHIBITION
13:30 - 14:00
PANEL DISCUSSION ON PEPTIDE DRUG
14:00 - 14:30
RESERVED PRESENTATION
14:30 - 14:55
FROM PEPTIDES TO DRUGS: EXPANDING THE FRONTIERS OF MEDICINAL CHEMISTRY
Gerhard Müller
SpiroChem AG

Gerhard Müller

SpiroChem AG

  • Translating peptide hits into tractable leads and more drug-like candidate designs
  • Deploying peptidomimetic tools to reduce liabilities and improve target engagement
  • Refining macrocycles with tailored residues, linkers, and conformational control
14:55 - 15:00
Q&A SESSION ON MEDICINAL CHEMISTRY ADVANCES IN PEPTIDES
15:00 - 15:20
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:20 - 15:50
PANEL DISCUSSION ON PEPTIDE DRUG
15:50 - 16:15
SPPS SCALE-UP STRATEGY – FROM R&D TO MANUFACTURING; CONSIDERATIONS FOR UPSCALING PEPTIDE SYNTHESIS
Hanson Chang
CSBio

Hanson Chang

CSBio

  • Navigating shifts from mg to g and kg scale while anticipating process demands and timelines
  • Assessing synthesiser trade-offs, scale-up risks, and reproducibility across development stages
  • Planning early mg and g scale decisions that support smoother transfer into kg manufacturing
16:15 - 16:20
Q&A SESSION ON SPPS SCALE-UP FROM R&D TO MANUFACTURING
16:20 - 16:50
RESERVED PRESENTATION
16:50 - 17:20
RESERVED PRESENTATION
17:20 - 18:20
NETWORKING DRINKS RECEPTION
DAY 2 :
THURSDAY, 15 OCTOBER, 2026
08:00 - 08:30
MORNING REFRESHMENTS
08:30 - 08:40
OPENING ADDRESS
08:40 - 09:05
BREAKING DOWN SOLID TUMOUR BARRIERS WITH BISPECIFIC T-CELL ENGAGER
Stefan Scherer
3T Biosciences

Stefan Scherer

3T Biosciences

  • Targeting tumours via intracellular peptide-HLA with bispecific T-cell engagers
  • Identifying a novel wild-type pHLA target using ML-driven high-throughput screening
  • Demonstrating selective tumour lysis by 3T-403 with minimal off-target cytotoxicity
09:05 - 09:10
Q&A SESSION ON TARGETING SOLID TUMOURS WITH TCR-MIMETIC ENGAGERS
09:10 - 09:35
INTEGRATING GLP-1 THERAPY WITH LIFESTYLE SUPPORT: A COMMUNITY-BASED MODEL FOR SUSTAINABLE OUTCOMES
Lauren Connis
Oldham Active

Lauren Connis

Oldham Active

  • Mobilising exercise referral pathways to complement GLP-1 prescribing with lifestyle coaching
  • Safeguarding muscle mass during GLP-1 treatment via resistance training and adequate protein intake
  • Evidencing long-term GLP-1 patient outcomes through real-world community case studies
09:35 - 09:40
Q&A SESSION ON GLP-1 PATIENT OUTCOMES THROUGH COMMUNITY LIFESTYLE SUPPORT
09:40 - 10:05
TRANSFORMING PEPTIDE MANUFACTURING: HYBRID STRATEGIES AND SUSTAINABILITY
Machiel Zeeman
AmbioPharm

Machiel Zeeman

AmbioPharm

  • Integrating solid-phase and liquid-phase synthesis to improve peptide process efficiency
  • Enhancing fragment-based hybrid routes to increase purity and strengthen yield
  • Advancing more sustainable production while addressing the limits of traditional SPPS
10:05 - 10:10
Q&A SESSION ON HYBRID PEPTIDE MANUFACTURING
10:10 - 10:30
MORNING COFFEE BREAK IN THE EXHIBIT AREA
10:30 - 10:55
RISK-BASED STRATEGIES AND REGULATORY PERSPECTIVES IN PEPTIDE THERAPEUTICS
Ruxandra Ionescu
ProPharma Group

Ruxandra Ionescu

ProPharma Group

  • Prioritising peptide risks via systematic identification to support transparent risk-based approaches
  • Defining control strategies that justify manufacturing and formulation decisions
  • Clarifying developer and regulatory perspectives on peptide risk management
10:55 - 11:00
Q&A SESSION ON RISK-BASED APPROACHES FOR PEPTIDE DRUG DEVELOPMENT
11:00 - 11:25
CHEMICAL EVOLUTION OF (XENO)PEPTIDES FOR RNA DELIVERY AND GENOME EDITING
Ernst Wagner
Ludwig-Maximilians-Universität München

Ernst Wagner

Ludwig-Maximilians-Universität München

  • Forming LAF-XPs with dual pH response in varied topologies across four to six coupling steps
  • Achieving strong RNA delivery in full serum at a very low mRNA dose with roughly two particles per cell
  • Showing potent in vivo RNA activity and effective genome editing performance in mice
  • Linking SAXS, TEM, logD, and logP profiles with mechanism and biological performance
11:25 - 11:30
Q&A SESSION ON RNA DELIVERY AND GENOME EDITING WITH PEPTIDES
11:30 - 11:55
ORAL DELIVERY OF THERAPEUTIC PEPTIDES: FROM CONCEPT TO GLOBAL MARKET
Andreas Bernkop-Schnürch
University of Innsbruck

Andreas Bernkop-Schnürch

University of Innsbruck

  • Addressing challenges in peptide and protein drug delivery via oral administration
  • Improving self-emulsifying systems for oral peptide and protein bioavailability
  • Developing GLP-1 oral formulations and exploring their future commercial potential
11:55 - 12:00
Q&A SESSION ON ORAL PEPTIDE FORMULATION STRATEGIES
12:00 - 12:15
FEEDBACK AND RAFFLE DRAW
12:15 - 12:30
CLOSING REMARKS
12:30 - 13:30
NETWORKING LUNCH

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.